KLRK1 and COVID-19: Previously, we have also shown a decrease in the proportion of NKG2D+ NK cells in ICU and moderate patients with COVID-19 [43], that via IL-6 could reduce the activity of NK cells by suppressing the expression of NKG2D [81].